Vaccination with inactivated murine gammaherpesvirus 68 strongly limits viral replication and latency and protects type I IFN receptor knockout mice from a lethal infection
Human gammaherpesviruses such as Epstein-Barr virus (EBV) cause lifelong infections and associated diseases, including malignancies, and the development of an effective vaccine against this class of viral infections is of considerable interest. The murine herpesvirus 68 (MHV-68) model provides a use...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2004-03, Vol.22 (11), p.1433-1440 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1440 |
|---|---|
| container_issue | 11 |
| container_start_page | 1433 |
| container_title | Vaccine |
| container_volume | 22 |
| creator | Aricò, Eleonora Robertson, Kevin A. Belardelli, Filippo Ferrantini, Maria Nash, Anthony A. |
| description | Human gammaherpesviruses such as Epstein-Barr virus (EBV) cause lifelong infections and associated diseases, including malignancies, and the development of an effective vaccine against this class of viral infections is of considerable interest. The murine herpesvirus 68 (MHV-68) model provides a useful experimental setting to investigate the immune response to gammaherpesvirus infections and to evaluate the efficacy of vaccination strategies. In this study, we tested a heat-inactivated MHV-68 vaccine in immunocompetent mice as well as in B cell-deficient or type I IFN receptor knockout mice. Vaccination with heat-inactivated MHV-68 protected immunocompetent mice from the acute MHV-68 infection in the lung and strongly reduced the expansion of latently infected cells in the spleen and the development of splenomegaly. A similar inhibition of the acute viral replication in the lung was also observed in vaccinated B cell-deficient mice. Of note, the inactivated MHV-68 vaccine completely protected type I IFN receptor knockout mice from the infection with a lethal dose of MHV-68. |
| doi_str_mv | 10.1016/j.vaccine.2003.10.015 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71796456</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X03007540</els_id><sourcerecordid>71796456</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-fa101186d65b118e57711c54c3dbd2ca0843c19a016e7fa367e6e4ca5499aafa3</originalsourceid><addsrcrecordid>eNqFkcFu1DAQhiMEotvCI4AsIXrLYiexk5xQVVFYqYILIG7WrDPpepvEwXYW7TvxkEy6kUBcerI9-eazM3-SvBJ8LbhQ7_brAxhjB1xnnOdUW3MhnyQrUZV5mklRPU1WPFNFWgj-4yw5D2HPOZe5qJ8nZ0JylUulVsnv7w8WiNYN7JeNO0YHE-0BIjasnzzdwO6g72GHfsRwsH4KTFUsRO-Gu-7IOtvbGBh9gI55HDtrTjYYGtaRZjDHh_3oXURDaDyOyDZsc_OZeINjdJ7dD87cuymy3hpkrXc9A9Zh3JHUDi31kfJF8qyFLuDLZb1Ivt18-Hr9Kb398nFzfXWbmkLymLZAExKVapTc0oqyLIUwsjB5s20yA7wqciNqoDFi2UKuSlRYGJBFXQNQ4SK5PHnpyT8nDFH3NhjsOhjQTUGXoqxVIdWjIHGZyEtJ4Jv_wL2b_EA_oYUsVF1yns2UPFHGuxA8tnr0tgd_1ILrOXW910vqek59LlPq1Pd6sU_bHpu_XUvMBLxdAAgGutbDYGz4h1OkKWbR-xOHNN2DRa-DsRQgNpaSirpx9pGn_AHBw9Co</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1546970025</pqid></control><display><type>article</type><title>Vaccination with inactivated murine gammaherpesvirus 68 strongly limits viral replication and latency and protects type I IFN receptor knockout mice from a lethal infection</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><source>MEDLINE</source><source>ProQuest Central UK/Ireland</source><creator>Aricò, Eleonora ; Robertson, Kevin A. ; Belardelli, Filippo ; Ferrantini, Maria ; Nash, Anthony A.</creator><creatorcontrib>Aricò, Eleonora ; Robertson, Kevin A. ; Belardelli, Filippo ; Ferrantini, Maria ; Nash, Anthony A.</creatorcontrib><description>Human gammaherpesviruses such as Epstein-Barr virus (EBV) cause lifelong infections and associated diseases, including malignancies, and the development of an effective vaccine against this class of viral infections is of considerable interest. The murine herpesvirus 68 (MHV-68) model provides a useful experimental setting to investigate the immune response to gammaherpesvirus infections and to evaluate the efficacy of vaccination strategies. In this study, we tested a heat-inactivated MHV-68 vaccine in immunocompetent mice as well as in B cell-deficient or type I IFN receptor knockout mice. Vaccination with heat-inactivated MHV-68 protected immunocompetent mice from the acute MHV-68 infection in the lung and strongly reduced the expansion of latently infected cells in the spleen and the development of splenomegaly. A similar inhibition of the acute viral replication in the lung was also observed in vaccinated B cell-deficient mice. Of note, the inactivated MHV-68 vaccine completely protected type I IFN receptor knockout mice from the infection with a lethal dose of MHV-68.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2003.10.015</identifier><identifier>PMID: 15063566</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Animals ; Antigens ; Applied microbiology ; B cell ; B-Lymphocytes - immunology ; B-Lymphocytes - physiology ; Biological and medical sciences ; Cell Line ; Colleges & universities ; Epstein-Barr virus ; Fundamental and applied biological sciences. Psychology ; Herpes viruses ; Herpesviridae - immunology ; Herpesviridae Infections - immunology ; Herpesviridae Infections - prevention & control ; Herpesvirus Vaccines - immunology ; Immune response ; Immune system ; Infections ; Interferon Type I - physiology ; Lung - virology ; Lymphocytes ; Medical research ; MHV-68 ; Mice ; Mice, Inbred C57BL ; Mice, Knockout ; Microbiology ; Murine gammaherpesvirus 68 ; Neutralization Tests ; Pathology ; Proteins ; Receptors, Interferon - genetics ; Receptors, Interferon - physiology ; Rodents ; Transplants & implants ; Type I IFN ; Vaccination ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Vaccines, Inactivated - immunology ; Virus Latency - immunology ; Virus Replication - physiology</subject><ispartof>Vaccine, 2004-03, Vol.22 (11), p.1433-1440</ispartof><rights>2003 Elsevier Ltd</rights><rights>2004 INIST-CNRS</rights><rights>Copyright Elsevier Limited Mar 29, 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c450t-fa101186d65b118e57711c54c3dbd2ca0843c19a016e7fa367e6e4ca5499aafa3</citedby><cites>FETCH-LOGICAL-c450t-fa101186d65b118e57711c54c3dbd2ca0843c19a016e7fa367e6e4ca5499aafa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1546970025?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,778,782,3539,27907,27908,45978,64366,64368,64370,72220</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15601545$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15063566$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aricò, Eleonora</creatorcontrib><creatorcontrib>Robertson, Kevin A.</creatorcontrib><creatorcontrib>Belardelli, Filippo</creatorcontrib><creatorcontrib>Ferrantini, Maria</creatorcontrib><creatorcontrib>Nash, Anthony A.</creatorcontrib><title>Vaccination with inactivated murine gammaherpesvirus 68 strongly limits viral replication and latency and protects type I IFN receptor knockout mice from a lethal infection</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Human gammaherpesviruses such as Epstein-Barr virus (EBV) cause lifelong infections and associated diseases, including malignancies, and the development of an effective vaccine against this class of viral infections is of considerable interest. The murine herpesvirus 68 (MHV-68) model provides a useful experimental setting to investigate the immune response to gammaherpesvirus infections and to evaluate the efficacy of vaccination strategies. In this study, we tested a heat-inactivated MHV-68 vaccine in immunocompetent mice as well as in B cell-deficient or type I IFN receptor knockout mice. Vaccination with heat-inactivated MHV-68 protected immunocompetent mice from the acute MHV-68 infection in the lung and strongly reduced the expansion of latently infected cells in the spleen and the development of splenomegaly. A similar inhibition of the acute viral replication in the lung was also observed in vaccinated B cell-deficient mice. Of note, the inactivated MHV-68 vaccine completely protected type I IFN receptor knockout mice from the infection with a lethal dose of MHV-68.</description><subject>Animals</subject><subject>Antigens</subject><subject>Applied microbiology</subject><subject>B cell</subject><subject>B-Lymphocytes - immunology</subject><subject>B-Lymphocytes - physiology</subject><subject>Biological and medical sciences</subject><subject>Cell Line</subject><subject>Colleges & universities</subject><subject>Epstein-Barr virus</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Herpes viruses</subject><subject>Herpesviridae - immunology</subject><subject>Herpesviridae Infections - immunology</subject><subject>Herpesviridae Infections - prevention & control</subject><subject>Herpesvirus Vaccines - immunology</subject><subject>Immune response</subject><subject>Immune system</subject><subject>Infections</subject><subject>Interferon Type I - physiology</subject><subject>Lung - virology</subject><subject>Lymphocytes</subject><subject>Medical research</subject><subject>MHV-68</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Mice, Knockout</subject><subject>Microbiology</subject><subject>Murine gammaherpesvirus 68</subject><subject>Neutralization Tests</subject><subject>Pathology</subject><subject>Proteins</subject><subject>Receptors, Interferon - genetics</subject><subject>Receptors, Interferon - physiology</subject><subject>Rodents</subject><subject>Transplants & implants</subject><subject>Type I IFN</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Vaccines, Inactivated - immunology</subject><subject>Virus Latency - immunology</subject><subject>Virus Replication - physiology</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkcFu1DAQhiMEotvCI4AsIXrLYiexk5xQVVFYqYILIG7WrDPpepvEwXYW7TvxkEy6kUBcerI9-eazM3-SvBJ8LbhQ7_brAxhjB1xnnOdUW3MhnyQrUZV5mklRPU1WPFNFWgj-4yw5D2HPOZe5qJ8nZ0JylUulVsnv7w8WiNYN7JeNO0YHE-0BIjasnzzdwO6g72GHfsRwsH4KTFUsRO-Gu-7IOtvbGBh9gI55HDtrTjYYGtaRZjDHh_3oXURDaDyOyDZsc_OZeINjdJ7dD87cuymy3hpkrXc9A9Zh3JHUDi31kfJF8qyFLuDLZb1Ivt18-Hr9Kb398nFzfXWbmkLymLZAExKVapTc0oqyLIUwsjB5s20yA7wqciNqoDFi2UKuSlRYGJBFXQNQ4SK5PHnpyT8nDFH3NhjsOhjQTUGXoqxVIdWjIHGZyEtJ4Jv_wL2b_EA_oYUsVF1yns2UPFHGuxA8tnr0tgd_1ILrOXW910vqek59LlPq1Pd6sU_bHpu_XUvMBLxdAAgGutbDYGz4h1OkKWbR-xOHNN2DRa-DsRQgNpaSirpx9pGn_AHBw9Co</recordid><startdate>20040329</startdate><enddate>20040329</enddate><creator>Aricò, Eleonora</creator><creator>Robertson, Kevin A.</creator><creator>Belardelli, Filippo</creator><creator>Ferrantini, Maria</creator><creator>Nash, Anthony A.</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20040329</creationdate><title>Vaccination with inactivated murine gammaherpesvirus 68 strongly limits viral replication and latency and protects type I IFN receptor knockout mice from a lethal infection</title><author>Aricò, Eleonora ; Robertson, Kevin A. ; Belardelli, Filippo ; Ferrantini, Maria ; Nash, Anthony A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-fa101186d65b118e57711c54c3dbd2ca0843c19a016e7fa367e6e4ca5499aafa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Animals</topic><topic>Antigens</topic><topic>Applied microbiology</topic><topic>B cell</topic><topic>B-Lymphocytes - immunology</topic><topic>B-Lymphocytes - physiology</topic><topic>Biological and medical sciences</topic><topic>Cell Line</topic><topic>Colleges & universities</topic><topic>Epstein-Barr virus</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Herpes viruses</topic><topic>Herpesviridae - immunology</topic><topic>Herpesviridae Infections - immunology</topic><topic>Herpesviridae Infections - prevention & control</topic><topic>Herpesvirus Vaccines - immunology</topic><topic>Immune response</topic><topic>Immune system</topic><topic>Infections</topic><topic>Interferon Type I - physiology</topic><topic>Lung - virology</topic><topic>Lymphocytes</topic><topic>Medical research</topic><topic>MHV-68</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Mice, Knockout</topic><topic>Microbiology</topic><topic>Murine gammaherpesvirus 68</topic><topic>Neutralization Tests</topic><topic>Pathology</topic><topic>Proteins</topic><topic>Receptors, Interferon - genetics</topic><topic>Receptors, Interferon - physiology</topic><topic>Rodents</topic><topic>Transplants & implants</topic><topic>Type I IFN</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Vaccines, Inactivated - immunology</topic><topic>Virus Latency - immunology</topic><topic>Virus Replication - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aricò, Eleonora</creatorcontrib><creatorcontrib>Robertson, Kevin A.</creatorcontrib><creatorcontrib>Belardelli, Filippo</creatorcontrib><creatorcontrib>Ferrantini, Maria</creatorcontrib><creatorcontrib>Nash, Anthony A.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aricò, Eleonora</au><au>Robertson, Kevin A.</au><au>Belardelli, Filippo</au><au>Ferrantini, Maria</au><au>Nash, Anthony A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vaccination with inactivated murine gammaherpesvirus 68 strongly limits viral replication and latency and protects type I IFN receptor knockout mice from a lethal infection</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2004-03-29</date><risdate>2004</risdate><volume>22</volume><issue>11</issue><spage>1433</spage><epage>1440</epage><pages>1433-1440</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Human gammaherpesviruses such as Epstein-Barr virus (EBV) cause lifelong infections and associated diseases, including malignancies, and the development of an effective vaccine against this class of viral infections is of considerable interest. The murine herpesvirus 68 (MHV-68) model provides a useful experimental setting to investigate the immune response to gammaherpesvirus infections and to evaluate the efficacy of vaccination strategies. In this study, we tested a heat-inactivated MHV-68 vaccine in immunocompetent mice as well as in B cell-deficient or type I IFN receptor knockout mice. Vaccination with heat-inactivated MHV-68 protected immunocompetent mice from the acute MHV-68 infection in the lung and strongly reduced the expansion of latently infected cells in the spleen and the development of splenomegaly. A similar inhibition of the acute viral replication in the lung was also observed in vaccinated B cell-deficient mice. Of note, the inactivated MHV-68 vaccine completely protected type I IFN receptor knockout mice from the infection with a lethal dose of MHV-68.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>15063566</pmid><doi>10.1016/j.vaccine.2003.10.015</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2004-03, Vol.22 (11), p.1433-1440 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71796456 |
| source | Elsevier ScienceDirect Journals Complete - AutoHoldings; MEDLINE; ProQuest Central UK/Ireland |
| subjects | Animals Antigens Applied microbiology B cell B-Lymphocytes - immunology B-Lymphocytes - physiology Biological and medical sciences Cell Line Colleges & universities Epstein-Barr virus Fundamental and applied biological sciences. Psychology Herpes viruses Herpesviridae - immunology Herpesviridae Infections - immunology Herpesviridae Infections - prevention & control Herpesvirus Vaccines - immunology Immune response Immune system Infections Interferon Type I - physiology Lung - virology Lymphocytes Medical research MHV-68 Mice Mice, Inbred C57BL Mice, Knockout Microbiology Murine gammaherpesvirus 68 Neutralization Tests Pathology Proteins Receptors, Interferon - genetics Receptors, Interferon - physiology Rodents Transplants & implants Type I IFN Vaccination Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, Inactivated - immunology Virus Latency - immunology Virus Replication - physiology |
| title | Vaccination with inactivated murine gammaherpesvirus 68 strongly limits viral replication and latency and protects type I IFN receptor knockout mice from a lethal infection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T13%3A39%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vaccination%20with%20inactivated%20murine%20gammaherpesvirus%2068%20strongly%20limits%20viral%20replication%20and%20latency%20and%20protects%20type%20I%20IFN%20receptor%20knockout%20mice%20from%20a%20lethal%20infection&rft.jtitle=Vaccine&rft.au=Aric%C3%B2,%20Eleonora&rft.date=2004-03-29&rft.volume=22&rft.issue=11&rft.spage=1433&rft.epage=1440&rft.pages=1433-1440&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2003.10.015&rft_dat=%3Cproquest_cross%3E71796456%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1546970025&rft_id=info:pmid/15063566&rft_els_id=S0264410X03007540&rfr_iscdi=true |